Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Sahm

Showing results (241-250 of 451) with videos related to

Pageof 46
Sort By:
Science Translational Medicine|March 4, 2026
Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostatGerhard Jungwirth, Junguo Cao, Yimin Pan, et al.
Journal of Neuro-Oncology|March 23, 2026
Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classificationClaire Delbridge, Helen X Hou, Thomas Hielscher, et al.
Neuro-Oncology Advances|July 3, 2024
Imaging meningioma biology: Machine learning predicts integrated risk score in WHO grade 2/3 meningiomaOlivia Kertels, Claire Delbridge, Felix Sahm, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 12, 2020
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysisChristian Mirian, Anne Katrine Duun-Henriksen, Tareq Juratli, et al.
Acta Neuropathologica|April 5, 2019
Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1Christian Thomas, Friederike Knerlich-Lukoschus, Harald Reinhard, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
Neuropathology and Applied Neurobiology|December 16, 2020
A case series of Diffuse Glioneuronal Tumours with Oligodendroglioma-like features and Nuclear Clusters (DGONC)Jessica C Pickles, Kshitij Mankad, Miren Aizpurua, et al.
Oncoimmunology|June 16, 2025
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastomaAlexandros Kourtesakis, Eileen Bailey, Hiu Nam Hannah Chow, et al.
Oncotarget|May 7, 2015
Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patientsAndreas Mock, Rolf Warta, Christoph Geisenberger, et al.
Acta Neuropathologica Communications|March 19, 2026
Profiling of rare immune cell populations and integrative analysis identify immune ecotypes in newly diagnosed meningiomasCatharina Lotsch, Nicoletta Giuliani Canizales, Lena Jassowicz, et al.
Pageof 46

Showing results (241-250 of 451) with videos related to

Sort By:
Pageof 46
Science Translational Medicine|March 4, 2026
Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostatGerhard Jungwirth, Junguo Cao, Yimin Pan, et al.
Journal of Neuro-Oncology|March 23, 2026
Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classificationClaire Delbridge, Helen X Hou, Thomas Hielscher, et al.
Neuro-Oncology Advances|July 3, 2024
Imaging meningioma biology: Machine learning predicts integrated risk score in WHO grade 2/3 meningiomaOlivia Kertels, Claire Delbridge, Felix Sahm, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 12, 2020
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysisChristian Mirian, Anne Katrine Duun-Henriksen, Tareq Juratli, et al.
Acta Neuropathologica|April 5, 2019
Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1Christian Thomas, Friederike Knerlich-Lukoschus, Harald Reinhard, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
Neuropathology and Applied Neurobiology|December 16, 2020
A case series of Diffuse Glioneuronal Tumours with Oligodendroglioma-like features and Nuclear Clusters (DGONC)Jessica C Pickles, Kshitij Mankad, Miren Aizpurua, et al.
Oncoimmunology|June 16, 2025
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastomaAlexandros Kourtesakis, Eileen Bailey, Hiu Nam Hannah Chow, et al.
Oncotarget|May 7, 2015
Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patientsAndreas Mock, Rolf Warta, Christoph Geisenberger, et al.
Acta Neuropathologica Communications|March 19, 2026
Profiling of rare immune cell populations and integrative analysis identify immune ecotypes in newly diagnosed meningiomasCatharina Lotsch, Nicoletta Giuliani Canizales, Lena Jassowicz, et al.
Pageof 46